Advancing patient care through the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR)

J Allergy Clin Immunol. 2020 Jan;145(1):28-37. doi: 10.1016/j.jaci.2019.11.012. Epub 2019 Nov 20.


Recent advances in rare disease research are accelerated by the work of consortia that have been supported by the National Institutes of Health. Development of such consortia rely on multidisciplinary relationships and engagement with patient advocacy groups, as well as the National Institutes of Health and industry and academic partners. In this rostrum we present the development of such a process that focuses on eosinophilic gastrointestinal diseases. Principal investigators, patient advocacy groups, research assistants, and trainees work together to perform natural history studies that promote clinical trial readiness tools, conduct clinical trials, train a new generation of investigators, and perform innovative pilot studies.

Keywords: Eosinophils; advocacy; allergy; consortium; esophagitis; gastrointestinal.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Biomedical Research*
  • Clinical Trials as Topic
  • Enteritis* / immunology
  • Enteritis* / pathology
  • Enteritis* / therapy
  • Eosinophilia* / immunology
  • Eosinophilia* / pathology
  • Eosinophilia* / therapy
  • Eosinophilic Esophagitis* / immunology
  • Eosinophilic Esophagitis* / pathology
  • Eosinophilic Esophagitis* / therapy
  • Gastritis* / immunology
  • Gastritis* / pathology
  • Gastritis* / therapy
  • National Institutes of Health (U.S.)
  • United States

Supplementary concepts

  • Eosinophilic enteropathy